Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jul 11;205:105381. doi: 10.1016/j.antiviral.2022.105381

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 1 — Boceprevir, JMX0286, JMX0301 and JMX0941 are potent inhibitors of SARS-CoV-2 3CLpro. A. Michaelis–Menten plot of 100 nM authentic SARS-CoV-2 3CLpro with various concentrations of FRET substrate in Tris buffer. The best-fit V_max = 64.11 nM/s; K_m = 68.48 μM. B. Chemical structure of boceprevir, JMX0286, JMX0301 and JMX0941. C. Dose dependent inhibition of FRET-based substrate digestion by boceprevir, JMX0286, JMX0301 and JMX0941.